SHERIDAN, WYOMING – June 18, 2025 – Dentsply Sirona has announced the appointment of Matthew E. Garth as Executive Vice President and Chief Financial Officer, effective May 30, 2025. The company strengthens its executive leadership at a pivotal time in its transformation strategy, bringing on board a finance veteran with nearly 30 years of experience across global corporations.
SHERIDAN, WYOMING – June 18, 2025 – Dentsply Sirona has reaffirmed its long-standing commitment to workplace diversity and equity by renewing its strategic partnership with Women in DSO® through 2025. The move reinforces the company's broader “BEYOND: Taking Action for a Brighter World” sustainability framework and its goal to foster inclusivity across the dental industry.
SHERIDAN, WYOMING – June 18, 2025 – Dentsply Sirona and High Point University (HPU) have announced a long-term collaboration that marks a significant step forward in the evolution of dental education, pairing cutting-edge technology with an innovative academic model designed to prepare practice-ready dental professionals.
Equipping the Next Generation with Practice-Ready Skills
SHERIDAN, WYOMING – June 18, 2025 – Dentsply Sirona has launched a pioneering CAD/CAM zirconia abutment block that uniquely merges high strength with superior esthetics for implant-based restorations. The CEREC Cercon 4D™ Multidimensional Zirconia Abutment Block debuts alongside the new Calibra® Abutment Resin Cement, delivering a streamlined, high-performance chairside workflow for dental professionals.
Innovative layering for natural-looking implant restorations
SHERIDAN, WYOMING – June 16, 2025 – Roche has unveiled promising Phase III results for its immunotherapy Tecentriq® (atezolizumab) combined with lurbinectedin (Zepzelca®) in the treatment of extensive-stage small cell lung cancer (ES-SCLC), offering new hope for a patient population with few effective treatment options and historically poor survival outcomes.
SHERIDAN, WYOMING – June 12, 2025 – Genentech, a biotechnology powerhouse and subsidiary of Roche, has confirmed the layoff of 143 employees at its South San Francisco headquarters, marking the latest phase in a year-long operational reshaping. The company disclosed the reduction via a Worker Adjustment and Retraining Notification (WARN), with job terminations set to take effect on July 14.
SHERIDAN, WYOMING – June 12, 2025 – In a strategic move signaling regulatory reform and modernization, FDA Commissioner Marty Makary and CBER Director Vinay Prasad have outlined a new four-year roadmap for the agency in The Journal of the American Medical Association (JAMA). Their article, “Priorities for a New FDA,” introduces a reform-focused agenda that emphasizes accelerated drug approval timelines, generative AI implementation, and a renewed focus on cost transparency and public health outcomes.
SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling final overall survival data from its phase III INAVO120 study, showing that the Itovebi™ (inavolisib)-based regimen reduces the risk of death by more than 30% in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The findings were presented at the 2025 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.
First PI3K Inhibitor to Prolong Survival in This Breast Cancer Subtype
SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling new data from its ongoing FENopta open-label extension study, confirming that its investigational therapy fenebrutinib continues to provide sustained disease suppression in patients with relapsing multiple sclerosis (RMS) for up to two years.
SHERIDAN, WYOMING – May 27, 2025 – Roche has received a significant endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which issued a positive opinion for Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant. This recommendation positions Roche to offer a first-line treatment solution for adult patients with PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer—an area with limited current treatment options.